The purpose of this research is to investigate study drug IW-6463 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). IW-6463 is not approved by the U.S. Food and Drug Administration for any use.

The study period will last for approximately 75 days and will include at least 3 to 6 on-site visits at the Children’s Hospital of Philadelphia (CHOP), where participants will be provided the study drug and monitored for safety.

For more information, please contact Sara Nguyen at

For More Information

Contact Us Online

Call (267) 426-6846

Related Centers and Programs